E
Esperion Therapeutics, Inc. (ESPR)
NGM – Real Time Price. Currency in USD
2.74
-0.11 (-3.86%)
At close: Mar 27, 2026, 4:00 PM EDT
2.72
-0.02 (-0.73%)
After-hours: Mar 27, 2026, 5:54 PM EDT
Get all premium features to the best stock analysis tool
NGM – Real Time Price. Currency in USD
2.74
-0.11 (-3.86%)
At close: Mar 27, 2026, 4:00 PM EDT
2.72
-0.02 (-0.73%)
After-hours: Mar 27, 2026, 5:54 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 1.54 | 2.52 | 8.0 | |
| Quick ratio | 1.19 | 1.78 | 7.0 | |
| Debt to Equity | N/A | -0.80 | 1.0 | |
| Debt to Assets | 0.62 | 0.73 | 3.0 | |
| Interest coverage | 3.77 | -13.90 | 9.0 | |
| Weighted average score | 5.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 75M | 116M | 332M | 403M | 403M |
| Gross Profit | 48M | 73M | 264M | 274M | 274M |
| Operating Income | -180M | -156M | 54M | 60M | 60M |
| Net Income | -234M | -209M | -52M | -23M | -23M |
| EBITDA | -179M | -155M | 54M | 60M | 60M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 45.97 | 89.03 | 10 |
| Next quarter | 15.26 | 106.57 | 9.5 |
| Current year | 1.39 | 167.13 | 6.5 |
| Next year | 8.8 | -28.66 | 3.5 |
| Weighted average score | 7.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 92.93 | 297.34 | 237.5 | 1155.6 | 10 |
| Y/Y | 143.73 | 390.04 | 300 | 229.44 | 10 |
| 3y average | 87.04 | 47.3 | 63.08 | 50.06 | 10 |
| 5y average | 38.36 | 13.52 | 34.69 | -4.52 | 7.3 |
| Weighted average score | 9.3 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Total debt $548.0M significantly exceeds cash reserves ($167.9M), raising financial stability concerns
Total current assets $462.6M exceed Total current liabilities $300.8M, highlighting excellent liquidity
Debt-to-equity ratio (-1.8) is well below the industry average (-0.8), showcasing prudent financial management
Interest coverage ratio (4x) indicates the company easily manages its debt payments
The company generates positive free cash flow $45.2M, supporting its financial health